Vifor Pharma

CSL Takes Vifor Pharma for $11.7 Billion

After days of speculation, it’s now official. Australian biopharmaceuticals manufacturer CSL has grabbed for and won the hand of Swiss Vifor Pharma. The boards of both companies have unanimously approved the $11.7 billion public tender offer, which looks certain to be accepted by Vifor’s shareholders. Its largest, Patinex, with 23%, has already agreed to tender.

Made in Switzerland – Exported Worldwide

Swiss Anti-Immigration Vote Could Impact Chemical Sector

Hikma Pharma, Vifor Pharma Enter into Licensing, Distribution Deal